No Data
Dong-E-E-Jiao Co.,Ltd.'s (SZSE:000423) Stock Is Going Strong: Is the Market Following Fundamentals?
zhongtai: In Q3 2024, traditional chinese medicine companies are experiencing temporary pressure, while end demand has slightly rebounded.
In the third quarter of 2024, traditional chinese medicine companies are experiencing temporary performance pressure, but gross margin is expected to improve upward from 2025.
Macquarie Starts Dong-E-E-Jiao at Outperform With 70 Yuan Price Target
The Strong Earnings Posted By Dong-E-E-JiaoLtd (SZSE:000423) Are A Good Indication Of The Strength Of The Business
Zheshang: Innovative drugs and blood products sectors may benefit from slow demand recovery on the demand side.
Zheshang has released research reports stating that the transition of old and new dynamics in the pharmaceutical industry will continue in the future. Areas with innovative drugs, supply-side structural reform, or a good layout (innovative drugs supporting industry chain, large infusion solutions, potent anaesthetics, blood products, pharmaceutical circulation, traditional Chinese medicine OTC) could benefit from the slow recovery on the demand side, potentially showing better growth prospects.
Dong-E-E-Jiao Co.,Ltd. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Dong-E-E-Jiao Co.,Ltd.'s (SZSE:000423) Shareholders Might Be Looking For Exit
